

EGFR Somatic Mutations in Lung Tumors: Radon Exposure and Passive Smoking in Former- and Never-Smoking U.S. Women

Masataka Taga^{1,2}, Leah E. Mechanic², Nobutoshi Hagiwara^{2,4}, Kirsi H. Vähäkangas⁵, William P. Bennett⁶, Michael C.R. Alavanja³, Judith A. Welsh², Mohammed A. Khan², Adam Lee⁷, Robert Diasio⁷, Eric Edell⁸, Aaron Bungum⁸, Jin Sung Jang⁸, Ping Yang⁹, Jin Jen⁸, and Curtis C. Harris²

Abstract

Background: Patients with lung cancer with mutations in EGF receptor (*EGFR*) tyrosine kinase have improved prognosis when treated with *EGFR* inhibitors. We hypothesized that *EGFR* mutations may be related to residential radon or passive tobacco smoke.

Methods: This hypothesis was investigated by analyzing *EGFR* mutations in 70 lung tumors from a population of never and long-term former female smokers from Missouri with detailed exposure assessments. The relationship with passive smoking was also examined in never-smoking female lung cancer cases from the Mayo clinic.

Results: Overall, the frequency of *EGFR* mutation was 41% [95% confidence interval (CI), 32%–49%]. Neither radon nor passive-smoking exposure was consistently associated with *EGFR* mutations in lung tumors.

Conclusions: The results suggest that *EGFR* mutations are common in female, never-smoking lung cancer cases from the United States, and *EGFR* mutations are unlikely due to exposure to radon or passive smoking. *Cancer Epidemiol Biomarkers Prev*; 21(6); 988–92. ©2012 AACR.

Introduction

Among never-smokers, lung cancer is the seventh leading cause of cancer death. A large proportion of lung cancer in never-smokers remains unexplained by established environmental risk factors. However, radon and passive smoke exposure were associated with lung cancer in never-smokers in several studies (for review, see ref. 1).

Lung cancer has a poor prognosis overall, but small-molecule inhibitors of EGF receptor (*EGFR*) result in

improved survival in some patients. Therapeutic response correlates with somatic mutations in the *EGFR* gene. Those mutations are inversely correlated with cigarette smoking and more frequently observed in never-smokers (for review, see ref. 2). We investigated the possibility that residential radon or passive smoking were associated with the presence of *EGFR* mutations in lung tumors in 2 populations of female never and long-term former smokers.

Methods

Study populations

The Missouri Women's Health Study case series included Caucasian lung cancer cases nested within a case-control study of never- and former-smoking women (3, 4). Patients with lung cancer from the Mayo Clinic were described previously (5). Cases were limited to Caucasian women to ensure comparability with the Missouri study.

EGFR mutation analysis

Missouri women. DNA previously isolated from microdissected tumor samples (4), available from 105 of 132 samples, was used for *EGFR* mutation analysis in the Laboratory of Human Carcinogenesis. Because of evaporation, the majority of DNA samples (74% or 78 of 105) were reconstituted using 10 μ L of Tris-EDTA buffer (pH 7.5). PCR amplification was conducted as a 50 μ L reaction including 2 μ L DNA stock solution, 1.25 U of Native Pfu DNA polymerase (Stratagene), 1 \times Pfu buffer, 300 nmol/L forward and reverse primers for either exon 19 or exon 21

Authors' Affiliations: ¹Department of Radiobiology/Molecular Epidemiology Radiation Effects Research Foundation, Hiroshima, Japan; ²Laboratory of Human Carcinogenesis, ³Department of Cancer, Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland; ⁴Department of Surgery I, Nippon Medical School Hospital, Tokyo, Japan; ⁵Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland; ⁶Department of Biology, Beckman Research Institute at the City of Hope, Duarte, California; ⁷Molecular Pharmacology and Developmental Therapeutics, and the Cancer Center, ⁸Pulmonary and Critical Care Medicine, and ⁹Department of Health and Human Sciences Research, Mayo Clinic, Rochester, Minnesota

Note: Work was conducted when M. Taga and N. Hagiwara were in the Laboratory of Human Carcinogenesis.

M. Taga and L.E. Mechanic contributed equally to this work and conducted the analyses of *EGFR* mutations.

Corresponding Author: Leah E. Mechanic, Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, 37 Convent Drive, Building 37, Room 3068, Bethesda, MD 20892. Phone: 301-496-8105; E-mail: mechanil@mail.nih.gov

doi: 10.1158/1055-9965.EPI-12-0166

©2012 American Association for Cancer Research.

Table 1. EGFR gene mutations in never- and former-smoking patients with lung cancer

Patient ID	Histology	EGFR exon	Mutation type	Codon(s)	Nucleotide change	Amino acid change
Missouri Women						
2	Adenocarcinoma	19	Deletion	del Glu746-Ala750		
6	Other/mixed	21	Point	858	CTG>CGG	Leu>Arg
48	Small cell carcinoma	21	Point	866	GAG>GAT	Glu>Asp
54	Adenocarcinoma	21	Point	858	CTG>CGG	Leu>Arg
56	Adenocarcinoma	19	Deletion	del Glu746-Ala750		
57	Adenocarcinoma	21	Point	858	CTG>CGG	Leu>Arg
60	Adenocarcinoma	21	Point	858	CTG>CGG	Leu>Arg
69	Adenocarcinoma	21	Point	858	CTG>CGG	Leu>Arg
71	Adenocarcinoma	21	Point	858	CTG>CGG	Leu>Arg
72	Adenocarcinoma	19	Deletion	del Glu746-Ala750		
74	Adenocarcinoma	21	Point	833	TTG>TTT	Leu>Phe
76	Adenocarcinoma	19	Deletion plus insertion	del Leu747-Pro753 (ins Ser) ^a		
78	Adenocarcinoma	19	Deletion plus insertion	del Leu747-Ala750 (ins Pro) ^a		
81	Adenocarcinoma	19	Point	743	GCT>ACT	Ala>Thr
88	Adenocarcinoma	21	Point (silent)	858 (silent)	CTG>CTT	Leu>Leu
95	Adenocarcinoma	19	Deletion	del Glu746-Ala750		
104	Adenocarcinoma	21	Point	864	GCG>GTG	Ala>Val
105	Adenocarcinoma	19	Deletion	del Glu746-Ala750		
126	Adenocarcinoma	19	Deletion	del Glu746-Ala750		
129	Bronchioalveolar carcinoma	19	Deletion	del Glu746-Ala750		
134	Adenocarcinoma	21	Point	858	CTG>CGG	Leu>Arg
135	Bronchioalveolar carcinoma	19	Deletion plus insertion	del Glu746-Ser752 (ins Val) ^a		
136	Adenocarcinoma	21	Point (silent)	848 (silent)	CCG>CCT	Pro>Pro
139	Other/mixed	19	Deletion	del Ser752-Ile759		
Mayo Clinic study						
921901995	Adenosquamous carcinoma	21	Point	858	CTG>CGG	Leu>Arg
921901997	Adenocarcinoma	21	Point	858	CTG>CGG	Leu>Arg
921902006	Bronchioalveolar carcinoma	21	Point	858	CTG>CGG	Leu>Arg
921902011	Adenocarcinoma	19	Deletion	del Glu746-Ala750		
921902017	Adenosquamous carcinoma	21	Point	858	CTG>CGG	Leu>Arg
921902018	Adenocarcinoma	19	Deletion	del Glu746-Ala750		
921902021	Bronchioalveolar carcinoma	19	Deletion plus insertion	del Leu747-Pro753 (ins Ser) ^a		
921902023	Adenocarcinoma	19	Deletion	del Glu746-Ala750		
921902024	Adenocarcinoma	21	Point	858	CTG>CGG	Leu>Arg
921902032	Adenocarcinoma	19	Deletion	del Glu746-Ala750		
921902033	Adenosquamous carcinoma	19	Deletion	del Glu746-Ala750		
921902049	Adenocarcinoma	19	Deletion	del Glu746-Ala750		
921902055	Adenocarcinoma	21	Point	858	CTG>CGG	Leu>Arg
921902063	Adenocarcinoma	19	Deletion plus insertion	del Leu747-Ala750 (ins Pro) ^a		
921902067	Adenocarcinoma	19	Deletion	del Glu746-Ala750		
921902070	Adenocarcinoma	19	Deletion	del Glu746-Ala750		
921902071	Adenocarcinoma	19	Deletion plus insertion	del Glu746-Thr751 (ins Val) ^a		
921902084	Adenocarcinoma	19	Deletion	del Glu746-Ala750		
921902086	Bronchioalveolar carcinoma	19	Deletion	del Glu746-Ala750		

(Continued on the following page)

Table 1. *EGFR* gene mutations in never- and former-smoking patients with lung cancer (Cont'd)

Patient ID	Histology	EGFR exon	Mutation type	Codon(s)	Nucleotide change	Amino acid change
921902118	Adenosquamous carcinoma	21	Point	858	CTG>CGG	Leu>Arg
921902119	Adenocarcinoma	21	Point	858	CTG>CGG	Leu>Arg
921902121	Adenocarcinoma	19	Deletion	del Glu746-Ala750		
921902132	Adenocarcinoma	19	Deletion	del Glu746-Ala750		
921902140	Adenocarcinoma	19	Deletion	del Glu746-Ala750		
921902148	Adenocarcinoma	19	Deletion	del Glu746-Ala750		
921902154	Adenocarcinoma	19	Deletion	del Glu746-Ala750		
921902157	Squamous cell carcinoma	19	Deletion	del Glu746-Ala750		
921902160	Squamous cell carcinoma	19	Deletion	del Glu746-Ala750		
921902161	Adenocarcinoma	21	Point	858	CTG>CGG	Leu>Arg
921902163	Adenocarcinoma	19	Deletion plus insertion	del Leu747-Ala750 (ins Pro) ^a		
921902171	Adenocarcinoma	21	Point	858	CTG>CGG	Leu>Arg
921902172	Adenocarcinoma	21	Point	858	CTG>CGG	Leu>Arg
921902175	Adenocarcinoma	21	Point	858	CTG>CGG	Leu>Arg
921902187	Adenocarcinoma	19	Deletion	del Glu746-Ala750		

^ains, Insertion of amino acid in parentheses.

of *EGFR*; primers were identical to those reported previously (6). Amplification was conducted using the following conditions: 95°C for 5 minutes followed by 40 cycles of 96°C for 45 seconds, 58°C for 1 minute, and 72°C for 1 minute; a terminal extension cycle of 5 minutes at 72°C was included. If initial PCR reactions failed to amplify, a second PCR amplification reaction was carried out using 5 µL of a 1:10 dilution of the PCR reaction mixture. Samples that failed the first series of amplifications were re-amplified using a second aliquot of genomic DNA. Overall, 32 (30%) of 105 genomic samples failed to amplify. DNA sequencing was conducted as per manufacturer's instructions on an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems) by NCI DNA MiniCore Facility using the PCR amplification primers. Forward and reverse sequences were 100% concordant.

Mayo clinic. *EGFR* mutations were analyzed at the Mayo Clinic as part of oncogene mutation screening using the OncoCarta Panel v1.0 (Sequenom) on the Sequenom MassArray Genetic Analysis platform following manufacturer's protocol. Data analysis was conducted using MassArray Typer Analyzer 4.0 software (Sequenom). Performance of the assay was evaluated against a panel of lung tumor samples and cell lines with previously identified mutations. *EGFR* gene mutation data were available for all 73 cases from the Mayo clinic study.

Statistical analysis

Samples with incomplete sequencing data for *EGFR* (e.g., failed amplification at one or more exons) were considered missing. The Mayo Clinic study had mutation data on additional *EGFR* exons compared with the Missouri study. Cases with mutations in exons other than 19 and 21 were considered wild-type for *EGFR* (N = 3).

Results were similar when they were considered mutant (data not shown).

Never-smokers were defined as persons who had either smoked <100 cigarettes or did not use any tobacco products during their lifetimes. To examine association of any exposure to passive smoking in the Missouri study, categories of exposure (<21, 21–52, and >52 pack-years) were combined and compared with 0 pack-years. Former-smokers in the Missouri study abstained from tobacco for at least 15 years before interview (3). In the Mayo Clinic study, passive smoke dosimetry included both adult and/or in childhood exposures. Data analysis was conducted by SAS version 9.1 (SAS Institute Inc.) using 2-sided tests in the Laboratory of Human Carcinogenesis.

Results

Twenty-four of the Missouri cases [34%; 95% confidence interval (CI), 23%–47%] and 34 of the Mayo clinic cases (47%; 95% CI, 35%–59%) had mutations detected in exons 19 or 21 of *EGFR* (Table 1). Overall, the mutation frequency was 41% (95% CI, 32%–49.0%).

While there was a difference in the quartiles of radon exposure associated with *EGFR* mutation ($P = 0.01$), this was not significant when exposure was dichotomized at the median ($P = 0.14$; Fisher exact test), and no difference was observed when considering radon as a continuous measure ($P = 0.16$) and there was no evidence for a dose-response relationship with radon exposure (Table 2).

In the Missouri Women's Health Study cases, there was an inverse association of *EGFR* mutations with any exposure to passive smoke, but no clear dose-response relationship was observed with passive-smoke exposure quantified in pack-years. In the Mayo Clinic population,

Table 2. Association of *EGFR* mutations with patient characteristics

	Missouri women (EGFR)		<i>P</i>	Mayo Clinic study (EGFR)		<i>P</i>
	–Mutation (N = 46)	+Mutation (N = 24)		–Mutation (N = 39)	+Mutation (N = 34)	
	<i>n</i> (%)	<i>n</i> (%)		<i>n</i> (%)	<i>n</i> (%)	
Histologic subtype						
Adenocarcinoma ^a	34 (74)	19 (80)	0.98 ^b	28 (72)	29 (85)	0.28 ^b
Bronchioalveolar carcinoma	4 (9)	2 (8)		4 (10)	3 (9)	
Squamous cell carcinoma	2 (4)	0 (0)		3 (8)	2 (6)	
Small cell carcinoma	1 (2)	1 (4)		0 (0)	0 (0)	
Other	5 (11)	2 (8)		4 (10)	0 (0)	
Age, y						
Median (IQR)	76 (64–79)	66 (61–78)	0.24 ^c	68 (57–75)	72 (67–79)	0.06 ^c
Missing	3	1				
Passive smoke						
No exposure	21 (47)	17 (74)	0.04 ^b	10 (32)	4 (15)	0.22 ^b
Any exposure	24 (53)	6 (26)		21 (68)	22 (85)	
Missing	1	1		8	8	
Passive smoke, pack-years						
No exposure	21 (47)	17 (74)	0.08 ^b	nd	nd	
<21	10 (22)	3 (13)				
21–52	11 (24)	1 (4)				
>52	3 (7)	2 (9)				
Missing	1	1				
Passive smoke (adult exposure)						
No exposure	nd	nd		11 (35)	8 (31)	0.78 ^b
Any exposure				20 (65)	18 (69)	
Missing				8	8	
Passive smoke (child exposure)						
No exposure	nd	nd		22 (71)	13 (50)	0.17 ^b
Any exposure				9 (29)	13 (50)	
Missing				8	8	
Radon exposure, Bq/m³						
4.8–33.3	13 (30)	5 (23)	0.01 ^b	nd	nd	
35.2–55.5	5 (11)	9 (41)				
56.2–82.7	9 (20)	6 (27)				
>82.7	17 (39)	2 (9)				
Missing	2	2				
Radon exposure, Bq/m³						
Median (IQR)	63.7 (30.5–94.1)	46.5 (37.0–57.4)	0.16 ^c	nd	nd	
Missing		2				

Abbreviations: IQR, interquartile range; nd, not determined.

^aFive of the adenocarcinomas in the Mayo Clinic study were adenosquamous histology.

^bFisher exact test.

^cWilcoxon 2-sample test.

no association was observed between *EGFR* mutations and adult exposure, childhood exposure, or any exposure to passive smoke (Table 2).

Discussion

Our data do not support the hypothesis that radon exposure contributes to mutations in *EGFR*. The mutation frequency appeared elevated at low-dose exposure and

diminished at higher exposure levels, but we noticed a similar trend with *TP53* mutations (4). The relationship of radon with lung cancer risk is thought to be linear (1), so our inverse trend between radon dose and *EGFR* mutations probably occurred by chance.

We observed an inverse association of passive-smoke exposure with *EGFR* mutations in lung tumors in the Missouri study, but this finding failed to replicate in

the Mayo Clinic never-smoker patient cohort. Previously, an inverse association with passive-smoke exposure as an adult or in childhood was observed (7). However, another study linked long-term exposure to passive smoking with excess *EGFR* mutations (8).

In conclusion, we observed a high frequency of *EGFR* mutations in lung tumors from never-smoking and long-term former-smoking women in the United States, but no association between *EGFR* mutations with passive-smoking or residential radon exposure.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: M. Taga, M.C.R. Alavanja, P. Yang, J. Jen, C.C. Harris

Development of methodology: L.E. Mechanic, N. Hagiwara, J.A. Welsh, R. Diasio, J.S. Jang

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M. Taga, N. Hagiwara, K.H. Vähäkangas, W.P. Bennett, M.C.R. Alavanja, A. Lee, R. Diasio, E. Edell, A. Bungum, P. Yang
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): L.E. Mechanic, M.A. Khan, P. Yang, C.C. Harris

References

- Samet JM, Avila-Tang E, Boffetta P, Hannan LM, Olivo-Marston S, Thun MJ, et al. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. *Clin Cancer Res* 2009;15:5626–45.
- Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of *EGFR* mutations in lung cancer. *Int J Clin Oncol* 2006;11:190–8.
- Alavanja MC, Brownson RC, Lubin JH, Berger E, Chang J, Boice JD Jr. Residential radon exposure and lung cancer among nonsmoking women. *J Natl Cancer Inst* 1994;86:1829–37.
- Vähäkangas KH, Bennett WP, Castren K, Welsh JA, Khan MA, Blomeke B, et al. p53 and K-ras mutations in lung cancers from former and never-smoking women. *Cancer Res* 2001;61:4350–6.
- Yang P, Wentzlaff KA, Katzmann JA, Marks RS, Allen MS, Lesnick TG, et al. Alpha1-Antitrypsin deficiency allele carriers among lung cancer patients. *Cancer Epidemiol Biomark Prev* 1999;8:461–5.
- Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, et al. *EGFR* mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. *J Clin Oncol* 2005;23:857–65.
- Lee YJ, Cho BC, Jee SH, Moon JW, Kim SK, Chang J, et al. Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. *J Clin Oncol* 2010;28:487–92.
- Kawaguchi T, Ando M, Kubo A, Takada M, Atagi S, Okishio K, et al. Long exposure of environmental tobacco smoke associated with activating *EGFR* mutations in never-smokers with non-small cell lung cancer. *Clin Cancer Res* 2011;17:39–45.

Writing, review, and/or revision of the manuscript: M. Taga, L.E. Mechanic, N. Hagiwara, K.H. Vähäkangas, W.P. Bennett, M.C.R. Alavanja, J.A. Welsh, E. Edell, P. Yang, J. Jen, C.C. Harris
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L.E. Mechanic, J.A. Welsh, P. Yang
Study supervision: P. Yang, J. Jen, C.C. Harris
Biospecimens acquisition: P. Yang
Design, development, and the analysis of the *EGFR* gene mutation status for all Mayo Clinic samples: J. Jen

Acknowledgments

The authors thank Karen MacPherson for bibliographic assistance.

Grant Support

The work was supported by Intramural Research Program of the NIH, NCI, and CCR. The support from the Mayo Clinic study was provided by the Mayo Foundation, Mayo Clinic Cancer Center, Center for Individualized Medicine, and NIH grants CA-77118 (Yang) and CA-80127 (P. Yang). The Radiation Effects Research Foundation (RERF), Hiroshima and Nagasaki, Japan is a private, nonprofit foundation funded by the Japanese Ministry of Health, Labour and Welfare (MHLW) and the U.S. Department of Energy (DOE), the latter in part through DOE Award DE-HS0000031 to the National Academy of Sciences. The views of the authors do not necessarily reflect those of the two governments.

Received February 8, 2012; accepted March 21, 2012; published OnlineFirst April 20, 2012.